Clinical Trials Directory

Trials / Completed

CompletedNCT01295580

Comparative Study of Safety and Efficacy of Two Hyaluronic Acids for the Treatment of Knee Osteoarthritis Pain

A Multicenter, Randomized, Double-blind, Parallel, Active-controlled Clinical Trial With Non-inferiority Comparison to Evaluate Efficacy and Safety of Intra-articular Injection of DUROLANE® vs. ARTZ® in Treatment of Knee Osteoarthritis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
349 (actual)
Sponsor
Bioventus LLC · Industry
Sex
All
Age
40 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the comparative safety and efficacy of intra-articular injection of hyaluronic acid, obtained from two different sources, in the treatment of osteoarthritic pain of the knee.

Detailed description

This is a multicenter, randomized, double blind, parallel-controlled clinical trial using a non-inferiority comparison to evaluate the efficacy and safety of an intra-articular injection of Durolane® vs Artz® in the treatment of knee osteoarthritis. Subjects will be randomized 1:1 to receive either Durolane or Artz. All subjects will be followed up for 26 weeks from the initial treatment.The screening period is expected to be up to 2 weeks in duration before the baseline visit. Each subject will provide a written informed consent and undergo a qualifying screening. Assessment at screening will include postero-anterior view of standing weight-bearing semi-flexed radiographs of the study knee. The osteoarthritis changes of the study knee will be graded 0,1,2,3 or 4 according to the Kellgren-Lawrence radiographic scoring criteria. Radiographic assessment will be made by an assigned and well trained investigator at each study center. The study knee and contralateral knee will use the Likert WOMAC 5-point scoring for pain assessment. Physical examination of the knees and vital signs will be performed (this examination will be repeated at end).

Conditions

Interventions

TypeNameDescription
DEVICEARTZHyaluronic acid (five 2.5 mL injections)
DEVICEDUROLANEHyaluronic acid stabilized (one 3.0 mL injection + four weekly 0 mL sham injections)

Timeline

Start date
2011-01-01
Primary completion
2011-08-01
Completion
2012-02-01
First posted
2011-02-14
Last updated
2021-04-09
Results posted
2021-04-09

Locations

7 sites across 1 country: China

Source: ClinicalTrials.gov record NCT01295580. Inclusion in this directory is not an endorsement.